ACHV — Achieve Life Sciences, Inc. stock price, charts and financials
QT66Achieve Life Sciences, Inc.Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
7.91
+0.49+6.60%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -1257.65 | Insider Own | - | Shs Outstand | 102.66M | Perf Week | 8.65% |
| Market Cap | 812.03M | Forward P/E | - | EPS next Y | -0.66 | Insider Trans | -0.03% | Shs Float | 87.47M | Perf Month | 5.19% |
| Enterprise Value | 639.03M | PEG | - | EPS next Q | -0.20 | Inst Own | - | Short Float | 18.80% | Perf Quarter | 47.57% |
| Income | -18.00M | P/S | 45.11 | EPS this Y | 99.88% | Inst Trans | - | Short Ratio | 9.18 | Perf Half Y | 95.79% |
| Sales | 18.00M | P/B | - | EPS next Y | 54.51% | ROA | -59.88% | Short Interest | 16.45M | Perf YTD | 59.15% |
| Book/sh | -0.15 | P/C | 4.34 | EPS next 5Y | - | ROE | -892.07% | 52W High | 8.64 -8.45% | Perf Year | 156.82% |
| Cash/sh | 1.82 | P/FCF | - | EPS past 3/5Y | - | ROIC | -21425.74% | 52W Low | 2.62 201.91% | Perf 3Y | 62.76% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.16% 5.20% | Perf 5Y | -0.50% |
| Dividend TTM | - | EV/Sales | 35.50 | EPS Y/Y TTM | -101323.39% | Oper. Margin | 0.00% | ATR (14) | 0.41 | Perf 10Y | -99.30% |
| Dividend Ex-Date | - | Quick Ratio | 0.95 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 56.15 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.95 | EPS Q/Q | -116.22% | SMA20 | 0.29% | Beta | 2.33 | Target Price | 14.00 |
| Payout | 0.00% | Debt/Eq | 0.68 | Sales Q/Q | - | SMA50 | 11.42% | Rel Volume | 1.01 | Prev Close | 7.42 |
| Employees | 28 | LT Debt/Eq | 0.50 | Earnings | Nov 05 | SMA200 | 50.11% | Avg Volume | 1.86M | Price | 7.91 |
| IPO Date | Oct 12, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -385.20% - | Net Debt/EBITDA | 0.29 | Volume | 1,871,063 | Change | 6.60% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-13-26 | Reiterated | Morgan Stanley | $13 | |
| Aug-12-26 | Reiterated | Raymond James | $20 → $18 | |
| Aug-12-26 | Reiterated | H.C. Wainwright | Buy | $12 |
| Jun-26-26 | Resumed | Raymond James | Strong Buy | $20 |
| Apr-20-26 | Initiated | Canaccord | Buy | $13 |
| May-13-24 | Reiterated | Oppenheimer | Outperform | $11 |
| Nov-16-22 | Reiterated | Maxim Group | Buy | $8.00 |
Latest News· Times ET
Sep-07-26
Sep-07-2612:20AM
Sep-03-26
Sep-03-2601:15PM
Sep-02-26
Sep-02-2612:24AM
Aug-14-26
Aug-14-2612:31PM
Aug-11-26
04:30AM
Aug-03-26
Aug-03-2604:30AM
Jul-31-26
Jul-31-2604:30AM
Jul-19-26
Jul-15-26
Jul-15-2604:02AM
Jul-09-26
Jul-09-2604:03PM
Jul-07-26
Jun-29-26
04:30AM
Achieve Life Sciences Joins Russell 2000® Indexglobenewswire.com
Jun-23-26
Company
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 18 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 18 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 10 | 32 | 16 | — | — | — | — | — | — | |
| Research and Development | 25 | 23 | 23 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -18 | -55 | -39 | — | — | — | — | — | — | |
| Interest Expense | 0 | 1 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 1 | 1 | — | — | — | — | — | — | |
| Net Income Before Taxes | -18 | -55 | -40 | — | — | — | — | — | — | |
| Income Taxes | -2 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -18 | -55 | -40 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -18 | -55 | -40 | — | — | — | — | — | — | |
| Net Income | -18 | -55 | -40 | — | — | — | — | — | — | |
| EPS (Recurring) | -1,257.65 | -1.25 | -1.24 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1,257.65 | -1.25 | -1.24 | — | — | — | — | — | — | |
| EPS (Diluted) | -1,257.65 | -1.25 | -1.24 | — | — | — | — | — | — | |
| EBITDA | -17 | -54 | -37 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | 100.00 | — | — | — | — | — | — | — | — | |
| Operating Margin | -100.00 | — | — | — | — | — | — | — | — | |
| Net Margin | -100.00 | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 0 | 44 | 32 | — | — | — | — | — | — | |
| Market Capitalization | — | 219 | 113 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stewart Richard Alistair | Director | Aug 19 '26 | Sale | 8.49 | 20,626 | 175,177 | 208,249 | Aug 21 |
| Oki Mark K | Chief Financial Officer | Sep 18 '25 | Option Exercise | 0.00 | 168,000 | 0 | 178,000 | Sep 22 |
| Oki Mark K | Chief Financial Officer | Sep 18 '25 | Sale | 2.92 | 50,060 | 146,175 | 127,940 | Sep 22 |
| Stewart Richard Alistair | Chief Executive Officer | Sep 18 '25 | Option Exercise | 0.00 | 455,000 | 0 | 358,376 | Sep 22 |
| Stewart Richard Alistair | Chief Executive Officer | Sep 18 '25 | Sale | 2.92 | 129,501 | 378,143 | 228,875 | Sep 22 |
| Wan Jerry | Principal Accounting Officer | Sep 04 '25 | Option Exercise | 0.00 | 68,200 | 0 | 46,764 | Sep 08 |
| Wan Jerry | Principal Accounting Officer | Sep 04 '25 | Sale | 2.77 | 14,070 | 38,974 | 32,694 | Sep 08 |
| KING THOMAS BRAXTON | Director | Sep 04 '25 | Option Exercise | 0.00 | 455,000 | 0 | 455,000 | Sep 08 |
| KING THOMAS BRAXTON | Director | Sep 04 '25 | Sale | 2.77 | 139,858 | 387,407 | 315,142 | Sep 08 |
| JACOBS CINDY | President & CMO | Sep 04 '25 | Option Exercise | 0.00 | 220,000 | 0 | 143,214 | Sep 08 |
| JACOBS CINDY | President & CMO | Sep 04 '25 | Sale | 2.77 | 27,629 | 76,532 | 115,585 | Sep 08 |
| Xinos Jaime | Chief Commercial Officer | Sep 04 '25 | Option Exercise | 0.00 | 138,000 | 0 | 95,286 | Sep 08 |
| Xinos Jaime | Chief Commercial Officer | Sep 04 '25 | Sale | 2.77 | 20,854 | 57,766 | 74,432 | Sep 08 |
| Oki Mark K | Chief Financial Officer | Mar 17 '25 | Buy | 2.89 | 10,000 | 28,887 | 10,000 | Mar 19 |
| Stewart Richard Alistair | Chieve Executive Officer | Mar 17 '25 | Buy | 2.86 | 10,000 | 28,598 | 60,876 | Mar 19 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.